Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 5/20 | 1.00 |
| ▸ | JMJD7 | P0C870 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.86 |
| ▸ | P4HB | P07237 | 7/20 | 0.82 |
| ▸ | MAPT | P10636 | 4/20 | 0.82 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.82 |
| ▸ | GRK6 | P43250 | 1/20 | 0.82 |
| ▸ | LMNA | P02545 | 3/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.77 |
| ▸ | HTT | P42858 | 2/20 | 0.77 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.77 |
| ▸ | USP2 | O75604 | 2/20 | 0.77 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.77 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15783085 | 0.90 | TP53 (0.82) | TP53JMJD7CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL14907817 | 0.90 | GRK6 (1.00) | TP53JMJD7CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL23854803 | 0.90 | TP53 (0.82) | TP53JMJD7CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL13836461 | 0.90 | P4HB (1.00) | TP53JMJD7CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL13836221 | 0.90 | P4HB (1.00) | TP53JMJD7CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL23875092 | 0.90 | TP53 (0.81) | TP53JMJD7CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL23854792 | 0.88 | TP53 (0.78) | TP53JMJD7CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL15783134 | 0.87 | P4HB (0.79) | TP53JMJD7CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL15783133 | 0.87 | P4HB (0.78) | TP53JMJD7CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL15783114 | 0.87 | P4HB (1.00) | TP53JMJD7CYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024073624-A2 | ANTIPROLIFERATIVE BETTI BASES AND PRODRUGS THEREOF | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2024-04-04 | — | — | WO | disclosed |
| US-20210300898-A1 | SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS | JNANA THERAPEUTICS INC. | 2021-09-30 | — | — | US | disclosed |
| US-20210300898-A1 | SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS | JNANA THERAPEUTICS INC. | 2021-09-30 | — | — | US | disclosed |
| US-20210299070-A1 | METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY | JNANA THERAPEUTICS INC. | 2021-09-30 | — | — | US | disclosed |
| US-20210299070-A1 | METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY | JNANA THERAPEUTICS INC. | 2021-09-30 | — | — | US | disclosed |
| EP-3079697-B1 | PROLYLHYDROXYLASE/ATF4 INHIBITORS FOR TREATING NEURAL CELL INJURY | UNIV CORNELL (US) | 2021-02-03 | — | — | EP | disclosed |
| US-20200360366-A1 | PROLYLHYDROXYLASE/ATF4 INHIBITORS AND METHODS OF USE FOR TREATING NEURAL CELL INJURY OR DEATH AND CONDITIONS RESULTING THEREFROM | CORNELL UNIVERSITY (US) | 2020-11-19 | — | — | US | disclosed |
| US-10716783-B2 | Prolylhydroxylase/ATF4 inhibitors and methods of use for treating neural cell injury or death and conditions resulting therefrom | CORNELL UNIVERSITY (US) | 2020-07-21 | — | — | US | disclosed |
| WO-2020061476-A1 | SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS | JNANA THERAPEUTICS, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
| US-20190256471-A1 | SMALL MOLECULE INHIBITORS OF BOTULINUM NEUROTOXINS | THE GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE SECRETARY OF THE AR (US) | 2019-08-22 | — | — | US | disclosed |
| US-20110301193-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110301193-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110294848-A1 | SMALL MOLECULE INHIBITORS OF BOTULINUM NEUROTOXINS | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2011-12-01 | — | — | US | disclosed |
| US-20110294848-A1 | SMALL MOLECULE INHIBITORS OF BOTULINUM NEUROTOXINS | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2011-12-01 | — | — | US | disclosed |
| US-20110224207-A1 | FLAVIVIRUS INHIBITORS AND METHODS FOR THEIR USE | GEORGETOWN UNIVERSITY (US) | 2011-09-15 | — | — | US | disclosed |
| US-20110224207-A1 | FLAVIVIRUS INHIBITORS AND METHODS FOR THEIR USE | GEORGETOWN UNIVERSITY (US) | 2011-09-15 | — | — | US | disclosed |
| WO-2010039538-A2 | FLAVIVIRUS INHIBITORS AND METHODS FOR THEIR USE | GEORGETOWN UNIVERSITY (US) | 2010-04-08 | — | — | WO | disclosed |
| WO-2009151972-A1 | SMALL MOLECULE INHIBITORS OF BOTULINUM NEUROTOXINS | , THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE ARMY, ON BEHALF OF U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND (US) | 2009-12-17 | — | — | WO | disclosed |
| US-20080292619-A1 | Pharmaceutical Composition Containing Meltrin Antagonist | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2008-11-27 | — | — | US | disclosed |
| EP-1797897-A1 | MEDICINAL COMPOSITION CONTAINING MELTRIN ANTAGONIST | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2007-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200360366-A1 | PROLYLHYDROXYLASE/ATF4 INHIBITORS AND METHODS OF USE FOR TREATING NEURAL CELL INJURY OR DEATH AND CONDITIONS RESULTING THEREFROM | ATF4, P4HTM, P4HA1 | TP53 2913/4885JMJD7 2485/4885CYP2D6 3264/4885 |
| US-20210300898-A1 | SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS | SNRPE, G3BP1, G3BP2 | TP53 6/4885JMJD7 3726/4885CYP2D6 4671/4885 |
| US-20110301193-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | EGFR, ERBB2, ERBB3 | TP53 230/4885JMJD7 307/4885CYP2D6 2533/4885 |
| US-20210299070-A1 | METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY | SLC19A1, SLC1A5, SLC1A2 | TP53 4180/4885JMJD7 3640/4885CYP2D6 2985/4885 |
| US-20110224207-A1 | FLAVIVIRUS INHIBITORS AND METHODS FOR THEIR USE | SERPINB1, SPINT2, MME | TP53 4517/4885JMJD7 1125/4885CYP2D6 4230/4885 |
| US-20190256471-A1 | SMALL MOLECULE INHIBITORS OF BOTULINUM NEUROTOXINS | RAC2, BTN3A1, GDI1 | TP53 3978/4885JMJD7 3208/4885CYP2D6 3729/4885 |
| US-10716783-B2 | Prolylhydroxylase/ATF4 inhibitors and methods of use for treating neural cell injury or death and conditions resulting therefrom | HIF1AN, EGLN3, EGLN2 | TP53 2633/4885JMJD7 2274/4885CYP2D6 3150/4885 |
| US-20110294848-A1 | SMALL MOLECULE INHIBITORS OF BOTULINUM NEUROTOXINS | RAC2, BTN3A1, GDI1 | TP53 3978/4885JMJD7 3208/4885CYP2D6 3729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.